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Inducible EGFR T790M-Mediated Gefitinib Resistance in
Non-small Cell Lung Cancer Cells Does Not Modulate
Sensitivity to PI103 Provoked Autophagy
Flavia F. Moreira-Leite, PhD,* Luke R. Harrison, PhD,* Alexandr Mironov, PhD,†
Ruth A. Roberts, PhD,‡ and Caroline Dive, PhD*
Introduction: Non-small cell lung cancer (NSCLC) with certain
activating mutations in the epidermal growth factor receptor
(EGFR) is sensitive to the small molecule EGFR tyrosine kinase
inhibitors gefitinib and erlotinib, although acquired resistance
eventually develops. Resistance is often mediated by acquisition
of the T790M mutation in the activated EGFR allele. The aim of
this study was to investigate in an EGFR tyrosine kinase inhibitor
sensitive NSCLC cell line model, the impact of induced EGFR
T790M expression on the cell biology and sensitivity to novel
therapeutic strategies.
Methods: Doxycycline inducible EGFR T790M-mediated drug
resistance was generated in the clinically relevant HCC827
NSCLC cell line. Cell fate, the activities of EGFR and down-
stream signaling molecules, and the sensitivity to downstream
inhibition of EGFR signaling networks were examined in the
presence or absence of induced EGFR T790M expression.
Results: Inducible EGFR T790M expression generated acquired
resistance to EGFR inhibitors in HCC827 cells as expected.
However, induced EGFR T790M expression did not affect activ-
ity of EGFR downstream signaling pathways or cell proliferation
under the conditions tested. Moreover, sensitivity to inhibition of
signaling molecules downstream of EGFR was unaffected by
induced EGFR T790M. Importantly, HCC827 cells remained
sensitive to class I phosphatidyl-inositol-3-kinase and mamma-
lian target of rapamycin inhibition, which provoked pronounced
autophagy, without significant apoptosis.
Conclusions: Phosphatidyl-inositol-3-kinase /mammalian target
of rapamycin inhibition is a potentially effective therapeutic
strategy against NSCLC with acquired resistance to EGFR inhi-
bition. However, the implications of drug-induced autophagy in
NSCLC need further exploration.
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Autophagy
(J Thorac Oncol. 2010;5: 765–777)
Epidermal growth factor receptor (EGFR) activity isfrequently deregulated in solid tumors affecting signal-
ing networks important for tumor formation, maintenance,
and development. This is mediated through activation of
downstream signaling components including protein ki-
nase B (PKB or Akt)/phosphatidylinositol 3-kinase (PI3K)
and extracellular signal-regulated kinase (ERK)/ERK ki-
nase (MEK).1 Patients with non-small cell lung cancer
(NSCLC) whose tumors harbor somatic and activation
mutations in EGFR exons 18–21 show dramatic clinical
responses to reversible EGFR tyrosine kinase inhibitors
(TKIs) gefitinib and erlotinib.2–4 Most prevalent of these
are a single amino acid substitution L858R and short
in-frame deletions in exon 19.5 These mutations are
more common in females with adenocarcinoma classed as
“never-smokers.”5
Despite initial response, patients with NSCLC with
activating EGFR mutations develop resistance to EGFR
TKIs.6 Approximately half of acquired resistance cases are
accounted for by acquisition of an EGFR T790M mutation,
which occurs in cis with the exons 18–21 activating
mutation.7,8 MET amplification is the second most preva-
lent event identified in this patient population,9,10 and rare
EGFR mutations L747S, D761Y, and T854A also decrease
sensitivity to gefitinib and erlotinib.11–13
EGFR T790M mutation mediated resistance to ge-
fitinib and erlotinib has been confirmed in vitro and in
mouse models.14–18 The target site for EGFR TKIs is the
T790 residue in EGFR located at the back of the adenosine
triphosphate (ATP) binding cleft. Mutation of this so-
called “gatekeeper” residue to a bulkier methionine was
believed to sterically hinder TKI binding.7 However, in
vitro, T790M mutation increases affinity of activated
EGFR mutants to ATP, while having a modest negative
effect on drug affinity for EGFR.19 These results implicate
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competitive inhibition in favor of ATP (rather than steric
hindrance) as the major contributor to T790M-mediated
drug resistance.19
Rare familial cases of lung cancer are associated with
germline T790M mutation in EGFR,20 and introduction of
T790M mutation into wild-type EGFR provided modest
increase in catalytic activity19 and enhanced its oncogenic
potential.18 In contrast, introduction of T790M mutation
on activated (L858R) EGFR decreased catalytic activity.19
Despite these results, when constitutively or transiently
expressed in model cell lines, T790M-containing double
mutants of EGFR display enhanced oncogenic properties
compared with single mutants.16,21,22 Although these ef-
fects should be mediated by enhanced activation of down-
stream signaling pathways, this was not observed in
all cell lines.16,23
Although cells expressing double mutants with
EGFR T790M are resistant to reversible EGFR TKIs, they
retain sensitivity to high concentrations of irreversible
EGFR inhibitors.24 The latter demonstrated limited activity
in mouse models of EGFR T790M-expressing lung cancer
and against clinical NSCLC with acquired resistance to
gefitinib or erlotinib.17,25 Combination of the irreversible
EGFR inhibitor HKI-272 with mammalian target of rapa-
mycin (mTOR) inhibitor rapamycin or Hsp90 inhibition
has shown promise in preclinical models against T790M-
mediated drug resistance.15,17,23
Another probable route to overcoming EGFR T790M-
mediated drug resistance would be direct pharmacological
inhibition of PI3K or MEK, i.e., vertical attack on the
EGFR pathway. MEK inhibition induces changes in the
proapoptotic protein BIMEL identical to those observed
during gefitinib/erlotinib induced apoptosis in NSCLC
cells sensitive to these agents.12,26,27 However, NSCLC
cells expressing activated EGFR mutants were insensitive
to MEK inhibitor PD0325901.26–28
Class I PI3Ks are also activated downstream of
ligand-bound EGFR, resulting in activation of PKB/Akt
and mTOR.29 In contrast to MEK inhibition, treatment
with the pan-PI3K inhibitors LY294002 and wortmannin
did not elicit apoptosis-associated changes in BIMEL in
NSCLC cells sensitive to EGFR TKIs. This was perhaps
surprising, because inhibition of PI3K/Akt signaling has
been correlated with decreased cell survival.30 However,
this concept relies mainly on experiments using PI3K
inhibitors with relatively broad selectivity. Recently, in-
hibitors targeted more specifically to different classes of
PI3K have been developed. One example, PI103 inhibits
class I PI3K and mTOR and showed promising preclinical
activity against malignant glioma.31,32
Treatment of different cancer cell lines with PI103
does not always result in apoptosis but often induces cell
cycle arrest.31,32 PI103 was also shown to induce autoph-
agy in U87MG and PC3 cancer cell lines.33 Autophagy,
(“self-eating” stimulated by unfavorable microenviron-
ments), is negatively regulated by Class I PI3Ks, through
activation of Akt and mTOR.34 Although a cell survival
role for autophagy has been established, autophagy-depen-
dent cell death has also been described as “type II pro-
grammed cell death.”35 Once autophagy is initiated, a
subsequent block of late stages in the process might drive
cells into apoptosis.33
To study EGFR T790M activity and drug sensitivity
in a clinically relevant cell line, inducible expression of an
activated EGFR mutant containing the T790M mutation
was generated in EGFR TKI sensitive HCC827 NSCLC
cells. This is, to our knowledge, the first report of inducible
expression of EGFR T790M in a relevant cell line. Induc-
ible systems have the advantage of being truly isogenic,
allowing specific effects of the expressed gene to be
dissected from underlying genetic differences between
control and expressing cells. The system of inducible
resistance to EGFR TKIs described here was used to study
the impact of EGFR T790M expression on cell prolifera-
tion, the activation of signaling pathways downstream of
EGFR, and the resultant sensitivity to inhibition of MEK,
PI3K, and mTOR. The ability of PI3K and mTOR inhibi-
tion to induce cytostasis, apoptosis, or autophagy in this
cellular context was evaluated, and the implications of
autophagy induction in the clinic will be discussed.
MATERIALS AND METHODS
Drugs and Antibodies
Gefitinib (Iressa) was obtained from AstraZeneca
(Alderley Park, UK). PI103, U0126, PD98059, and CL-
387785 were from Calbiochem. All drugs were dissolved
in dimethyl sulfoxide (DMSO) and stored at 20°C.
Doxycycline (Invitrogen, Paisly, UK) was dissolved in
H2O, stored at 20°C, and used at 100 ng/ml unless stated
otherwise. Antibodies against the following proteins were from
cell signaling: Akt, phospho-Ser-473-Akt, phospho-EGFR (all
phosphorylated residues), ERK1/2, phospho-ERK1/2 (Thr202/
Tyr204); p70 S6-kinase and phospho-Thr389-p70 S6 kinase and
poly ADP ribose polymerase (PARP). The following antibodies
were sourced as follows; EGFR (Santa Cruz, Santa Cruz, CA),
BIM (Calbiochem, Darmstadt, Germany), LC3 (Nanotools,
Hamburg, Germany), actin and FLAG-tag (Sigma, St. Louis,
MO), Src (Upstate, Waltham, MA), and Phospho-Tyr529-Src
and phospho-tyr418-Src (Invitrogen).
DNA Constructs
The EGFR coding sequence was amplified from the
pBSII-SK-EGFR plasmid kindly provided by Dr. William
Pao (MSKCC, New York, NY). EGFR coding sequences
were inserted into pTre2hyg (Clontech, Palo Alto, CA)
using the NheI and NotI cloning sites to produce pTre2hyg-
EGFR-746-750-FLAG (control) or pTre2hyg-EGFR-
746-750-T790M-FLAG. To insert the NheI site at the 5
of the EGFR coding sequence, the following forward
primer was used: 5-GCA ATG GCT AGC ACC ATG
CGA CCC TCC GGG ACG-3. A FLAG-tag (DYKDHD)
followed by a NotI site were inserted at the 3 end of
the EGFR coding sequence using the following primer:
5-GCA ATG GCG GCC GCC TAC TTG TCA TCG TCA
TCC TTG TAA TCA CCT GCT CCA ATA AAT TC 3.
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Site-directed mutagenesis was performed by polymerase
chain reaction using the following primers: 5-GTC GCT
ATC AAG ACA TCT CCG AAA GCC-3 (in-frame dele-
tion of amino acids 746–750) and 5 GTG CAG CTC ATC
ATG CAG CTC ATG CCC 3 (T790M mutation). Poly-
merase chain reaction products were fully sequenced after
ligation into pTre2hyg vector. The Module 1 plasmid
(pN1pactin-rtTA2S-M2-IRES-EGFP)36 confers constitu-
tive polycistronic expression of the tetracycline reverse
transcriptional transactivator rtTA2S-M2 (“tet-on”) and the
eGFP gene and resistance to G418.
Cell Culture and Production of Stable
Cell Lines
HCC827 cells were from DSMZ (Braunschweig, Ger-
many). H3255 cells were a gift from Dr. Ming-Sound Tsao
(OCI, Toronto, Canada). All cells were maintained in RPMI
medium with 10% fetal bovine serum (FBS), which was not
supplemented with insulin-like growth factor in any experi-
ments. All experiments were performed in the presence of
FBS unless otherwise stated. For stable cell line generation,
HCC827 cells were electroporated with the Module 1 plasmid
and selected with 600 g/ml G418. Cells positive for eGFP
(i.e., also expressing rtTA2S-M2) were selected by fluores-
cence activated cell sorting. These “HCC827-M1” cells were
subsequently transfected with pTre2hyg-EGFR-746-750-
FLAG (control) or pTre2hyg-EGFR-746-750-T790M-
FLAG and selected with 50 g/ml hygromycin and 600
g/ml G418. Inducible expression of EGFR 746-750 in
HCC827 cells (which already express this protein) was used
as a control to evaluate the effect of increased exogenous
expression of the deletion mutation alone when compared
with the deletion mutation with added T790M (del746-750/
T790M).
Stably transfected cell populations were cloned by
low density seeding in a 1:1 mixture of conditioned and
fresh media containing G418 and hygromycin as above.
Clones capable of inducible expression of EGFR mutants
were identified by Western blotting for EGFR-FLAG
expression.
Western Blotting
Cells were prepared for Western blotting by direct lysis
in sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis sample buffer (62.5 mmol/L Tris [pH 6.8], 2% SDS,
10% glycerol, and 5% b-mercaptoethanol) or by extraction in
cell lysis buffer (cell signaling) followed by protein quanti-
fication using the bicinchoninic acid assay (Pierce) and lysis
in Laemmli sample buffer. Protein samples were run into
SDS-polyacrylamide gel electrophoresis gels and transferred
to polyvinylidene fluoride membranes. Membranes were
probed with primary antibodies overnight at 4°C and with
secondary antibodies conjugated to horseradish peroxidase
for 1 hour at room temperature. Blots were developed by
enhanced chemiluminescence and photographed using a Fu-
jifilm Dark Box II and the Image Reader LAS-1000 Plus
software.
3-(4,5-Dimethylthiazol-2-yl)-2,
5-Diphenyltetrazolium Bromide (MTT) Assay
Cells were tested for sensitivity to different compounds
using the MTT assay. Briefly, cells were seeded onto 96-well
plates at a density of 2.5  103 cells per well and allowed to
attach for 24 hours at 37°C before drug treatment. After 72
hours of drug exposure, the medium was removed and re-
placed with 50 L of 3 mg/ml MTT (Sigma) in phosphate
buffered saline. Cells were incubated in the MTT solution for
4 hours at 37°C, after which it was removed, and 100 L
DMSO were added per well to solubilize the formazan
product. After solubilization, 25 L of Tris-HCl pH 10.5
were added per well, and the plates were read in a Multiskan
EX plate reader with em 540 nm. Data were analyzed using
the GraphPad Prism software.
Cell Proliferation Analysis
Cells were plated into six-well plates at 1  105
cells/well and allowed to attach for 24 hours. Thereafter,
medium was changed for: RPMI supplemented with FBS,
with or without 100 ng/ml of doxycycline; or FBS-free
RPMI (serum starvation), with or without 100 ng/ml of
doxycycline. Before serum starvation, cells were washed
twice in FBS-free RPMI. Cell counts were performed in an
ADAM cell counter (Digital Bio) every 24 hours for 96
hours after addition of medium  doxycycline. Medium
was changed at 48 hours to prevent growth arrest. Data
were analyzed using the GraphPad Prism software.
Transmission Electron Microscopy (TEM)
Drug-treated cells plated on 10 cm2 cell culture
dishes were fixed with 2% EM Grade Glutaraldehyde in
0.2 M HEPES buffer, pH 7.4 for 2 hours at room temper-
ature. Cells were scraped, transferred to tubes, and post-
fixed with 1% osmium tetroxide in 0.1 M sodium cacody-
late buffer for 1 hour and then with 1% uranyl acetate for
1 hour in the dark. Dehydration in a series of 50 to 100%
ethanol and 100% propylene oxide was followed by em-
bedding in TAAB LV resin. Ultrathin sections cut using a
Reichert Ultracut S ultramicrotome were stained with lead
citrate before observation in a FEI Tecnai 12 Bio Twin
transmission electron microscope at 80 kV.
Light Microscopy
The acidophilic dye Lysotracker green (Molecular
Probes) was used to identify acidic vesicles in drug-treated
cells. HCC827 cells were plated onto glass coverslips and
drug-treated with 3 M PI103 for 16 hours at 37°C.
Lysotracker green (50 nM) was added 15 hours after
treatment. Real-time imaging of cells in medium without
Lysotracker green was performed using a Zeiss Axiovert
200 M light microscope equipped with a Roper Cascade
512B cooled charge coupled device camera. Images were
analyzed using the software Metamorph.
Flow Cytometry
HCC827 or H3255 cells were treated with different
concentrations of PI103 for 16 hours before quantitation of
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the cellular accumulation of acidic vesicles. After 15 hours
of treatment, fresh medium was provided containing Ly-
sotracker green (100 nM) and the appropriate concentra-
tion of PI103. At the end of the treatment period, cells
were trypsinized, spun, and resuspended in 400 L of
phosphate buffered saline before analysis in a BD FACS-
Calibur flow cytometer (ex 488 nm, em 530  30 nm).
Flow cytometric data were analyzed using the FlowJo
software (BD).
RESULTS
HCC827 Clones Inducibly Expressing
EGFR-Del/T790M Were Resistant to Gefitinib
and Less Sensitive to CL-387785
HCC827 NSCLC cells express an activated EGFR
mutant (exon 19 in-frame deletion of amino acids 746–750,
hereafter referred to as EGFR-Del). These cells are sensitive
to gefitinib and erlotinib and were derived from a lung
adenocarcinoma of a nonsmoking woman.37,38 Therefore,
HCC827 cells exhibit the clinicopathologic characteristics of
NSCLC sensitive to EGFR TKIs.
HCC827 clones capable of inducible expression of
EGFR mutants were generated by two steps of transfor-
mation and selection, and tested for inducible expression
of FLAG-tagged EGFR-Del or EGFR-Del/T790M by
Western blotting. Two representative clones of each type
were selected with the lowest expression of FLAG-EGFR
in the absence of doxycycline (Figure 1A). These clones
also showed homogeneous expression of the FLAG-tagged
protein by immunofluorescence (Figure S1). For simplic-
ity, the clones chosen to be used in further studies were
renamed D1 and D2 (for EGFR-Del-FLAG clones 1 and 2)
and T1 and T2 (for EGFR-Del/T790M-FLAG clones 1 and
2). Parental cells did not express FLAG, and none of the
protein levels were altered by the presence or absence of
doxycycline. All clones showed a clear increase in total
levels of EGFR protein after treatment with doxycycline,
which was accompanied by increased levels of phosphor-
ylated EGFR (Figures 1A and S2). Densitometric analysis
on the Western blots shown in Figure S2 indicated that
induction of EGFR-Del/T790M (with 100 ng/ml doxycy-
cline) resulted in no more than a twofold increase in the
expression of EGFR. Treatment of parental cells with
gefitinib or CL-387785 caused marked inhibition of p-
EGFR, p-Akt, and p-ERK but did not affect the levels of
any other proteins, consistent with inhibition of EGFR
signaling pathway. EGFR, ERK 1 and 2, and Akt remained
active (as determined by phosphorylation) after treatment
of clones T1 and T2 (but not D1 and D2) with 1 M
gefitinib in the presence of doxycycline. In contrast, EGFR
pathway inactivation (measured by dephosphorylation of
EGFR, Akt, and ERK1/2) occurred in all clones after
treatment with 1 M of the EGFR irreversible inhibitor
CL-387785 (Figure 1A).
Parental HCC827 cells were sensitive to gefitinib in
MTT assays measured 72 hours after drug exposure (Fig-
ure 1B). Clones D1 and D2 showed similar sensitivity to
gefitinib as parental cells, even after induced EGFR-Del
expression. In contrast, clones T1 and T2 showed marked
doxycycline-dependent resistance to gefitinib (IC50 5
M) and decreased sensitivity to CL-387785 (Figure 1B).
A small decrease in gefitinib sensitivity was observed
in T clones without doxycycline, probably due to residual
EGFR-Del/T790M expression in these conditions. Induced
EGFR-Del/T790M-FLAG expression, gefitinib resistance,
and decreased sensitivity to CL-387785 were doxycy-
cline concentration-dependent and reached maximal levels
after treatment with 12.5 to 25 ng/ml of doxycycline
(Figure S2).
Induced EGFR-Del/T790M Expression Did Not
Provide a Clear Cell Proliferation Advantage to
HCC827 Cells in Culture
The isogenic, clinically relevant HCC827 cell model
described here is ideally suited to identify changes in
proliferation and signaling conferred by EGFR T790M.
Selected clones were grown in medium containing 10%
FBS or in serum-free medium for 96 hours, in the presence
or absence of doxycycline, to determine whether EGFR-
Del/T790M induction conferred a proliferation advantage.
No significant changes in proliferation were seen in any of
the clones tested and parental cells, although slight prolif-
eration changes could be attributed to clonal variation
(Figure 2A). Proliferation indexes are shown in Table S1.
In agreement with the cell proliferation analysis, no
obvious increase in ERK1/2 or Akt phosphorylation was
observed when T clones were treated with doxycycline
(Figure 1A), despite the fact that EGFR phosphorylation at
seven different tyrosine residues was increased in all
clones in these conditions (Figure 2B). Phosphorylation at
tyrosine 1045 of EGFR is required for down-regulation of
EGFR signaling by internalization and degradation, and
low levels of phosphorylation at this site probably contrib-
ute to the potency of signaling of activated EGFR mu-
tants.39 After treatment with doxycycline, T clones showed
a greater increase in phosphorylation of tyrosine 1045 than
D clones (Figure 2B).
To our knowledge, the only report of differential
signaling activation resulting from the addition of T790M
mutation to activated EGFR was the increased activation
of c-Src in NIH3T3 cells expressing EGFR double mutants
containing the T790M mutation.16 These cells also became
rounded and less substrate adherent when compared with
those expressing single (activated) mutants.16 These
changes were not confirmed in this study: activating phos-
phorylation of c-Src at the tyrosine residue 418 was not
detected in D or T clones grown in the presence or absence
of doxycycline (Figure S3). In contrast, the inhibitory
phosphorylation of tyrosine 529 in c-Src was readily de-
tected in all clones and conditions (Figure S3). This
suggests that c-Src is inactive in the clinically relevant
HCC827 cells (in routine culture conditions), even after
inducible expression of EGFR T790M. In agreement with
this, no morphologic transformation was observed after
treatment of D or T clones with doxycycline (not shown).
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HCC827 Parental Cells and Clones Were Not
Sensitive to MEK Inhibition But Were Sensitive
to Class I PI3K Inhibition by PI103
A logical approach to overcome EGFR T790M-
mediated drug resistance is to target downstream signaling
molecules such as MEK, PI3K, or mTOR. In this study,
two MEK inhibitors (U0126 and PD98059) and one PI3K/
mTOR inhibitor (PI103) were evaluated in parental
HCC827 cells and in T and D clones, in the presence or
absence of doxycycline. Importantly, although PI103 in-
hibits class I PI3Ks preferentially,32 it most likely also
inhibits mTOR (both mTORC1 and mTORC2 complexes)
at the highest concentrations used here.31
HCC827 parental and clonal cell lines were resistant to
MEK inhibitors at concentrations that span the IC50 of most
cancer cell lines40 (Figure 3A and Table 1). In contrast, these
FIGURE 1. Inducible expression of EGFR T790M in HCC827 cells keeps the EGFR pathway active after gefitinib treatment,
resulting in resistance to this drug. A, D and T clones were grown in the presence or absence of doxycycline for 24 hours,
treated with 1 M gefitinib or CL-387785 for 3 hours, and prepared for Western blotting for detection of the FLAG-tagged
EGFR, EGFR, ERK1/2, and Akt. The activated forms of these proteins—phospho-Tyr1068-EGFR, phospho-Ser473-Akt, and phos-
pho-Thr202/Tyr204–ERK1/2—are represented as P-EGFR, P-Akt, and P-ERK1/2, respectively. Actin was used as a loading con-
trol. B, D and T clones were treated with increasing concentrations of gefitinib or CL-387785 for 72 hours, in the presence or
absence of doxycycline, and then subjected to MTT assays for drug sensitivity. Data in the y axis were represented as the %
Abs. relative to that of the DMSO-treated control. EGFR, epidermal growth factor receptor; DOX, doxycycline; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DMSO, dimethyl sulfoxide.
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FIGURE 2. Cell proliferation and the EGFR phosphorylation pattern were not affected by inducible expression of EGFR T790M in
HCC827 cells. A, Cell proliferation of D and T clones was monitored for 96 hours in the presence or absence of FBS and/or doxycy-
cline in the culture medium. Fresh medium was added at 48 hours to prevent cell cycle arrest. B, Clones were grown for 24 hours
in the presence or absence of doxycycline and treated with gefitinib for 3 hours before sample preparation for Western blotting for
total or phosphorylated EGFR. Note that the amino acid numbering used to describe phosphorylated tyrosine residues in EGFR dis-
regards its 24-amino acid long N-terminal signal sequence. EGFR, epidermal growth factor receptor; FBS, fetal bovine serum; DOX,
doxycycline; DMSO, dimethyl sulfoxide.
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cells were sensitive to PI103, with IC50 values in the range of
0.3 to 0.8 M (Figure 3A and Table 1). A different EGFR
TKI-sensitive cell line (H3255, which expresses EGFR
L858R) was treated with U0126 or with PI103 to verify if
sensitivity to PI3K inhibition was unique to HCC827 cells or
was found in other NSCLC cells dependent on an activating
EGFR mutant. Although H3255 cells were less resistant to
MEK inhibition than HCC827 (IC50  7.84 M for U0126),
their sensitivity to PI103 was in the same range as for
HCC827 cells (Table 1).
Phosphorylation of ERK1/2 after treatment with
PD98059 and U0126 was examined as a proof of mechanism
and pharmacodynamic biomarker of the activity of the MEK
inhibitors used. BIMEL phosphorylation and protein level
were also examined before and after treatment with MEK
inhibitors. Treatment with 10 or 20 M of U0126 for 20
FIGURE 3. HCC827 parental cells and clones are sensitive to PI3K/mTOR inhibition by PI103 but are resistant to MEK inhibi-
tion. A, Cells were treated with increasing concentrations of U0126 or PI103 for 72 hours, in the presence or absence of doxy-
cycline, and subjected to the MTT assay. Data in the y axis were represented as the % absorbance relative to that of the
DMSO-treated control. B and C, HCC827 or H3255 cells were treated with PI103, U0126, or PD98059 for 16 hours and pre-
pared for Western blotting for the detection of total and phosphorylated ERK1/2, Akt, p70 S6K, or total BIM (only the bands
corresponding to the BIMEL isoform are shown). Actin was used as a loading control. In B, drug concentrations are displayed
parenthetically. MEK, extracellular signal-regulated kinase kinase; mTOR, mammalian target of rapamycin; MTT, 3-(4,5-dim-
ethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ERK, extracellular signal-regulated kinase; PI, PI103; U0, U0126; PD,
PD98059.
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hours resulted in a clear decrease in ERK phosphorylation, an
increase in BIMEL protein levels, and a clear mobility shift in
this protein compatible with dephosphorylation (Figure 3B).
UO126 at concentrations of 1.25, 2.5, and 5 M did not
provoke a decrease in ERK phosphorylation in HCC827
cells. These data (Figure S4) together with that presented in
Figure 3B show that whether ERK was phosphorylated
(UO126 10 M) or not (UO126 10 M or 20 M), there
was no effect on cell population growth. Therefore, at the
highest concentration of U0126 used in the MTT assay (10
M), apoptosis-associated changes in BIMEL identical to
those reported in the literature26,27 were observed, despite the
fact that cells were insensitive to MEK inhibition (Figure 3A).
PD98059 was not as effective as U0126 in decreasing ERK
phosphorylation and modulating BIMEL, consistent with its
reduced potency compared with U0126.40
HCC827 and H3255 cells were considerably more
sensitive to PI3K/mTOR inhibition than to MEK inhibition
(Figure 3A and Table 1). Lower concentrations of PI103 were
needed to reduce phosphorylation of Akt and p70S6K (a
biomarker of mTOR activity) in HCC827 compared with
H3255 (Figure 3C), despite the fact that these cell lines were
similarly sensitive to PI103. Activating phosphorylation of
Akt or p70S6K was undetectable in all cell lines after treat-
ment with 3 M PI103 (Figure 3B).
UO126 when applied as a single agent at 10 M had
little or no effect on HCC827 (parental and induced clones)
cell growth, despite clear inhibition of p-ERK (Figure 3B)).
The effect of combining UO126 (10 M) with PI-103 was
investigated in parental and induced and uninduced clones
(D1, D2, T1, and T2). There was no significant effect of
combining this PI3K inhibitor with this MEK inhibitor in
these cells (Figure S5).
PI103 Promoted Autophagy in HCC827 and
H3255 Cells
Recently, PI103 treatment of two cancer cell lines
was shown to induce autophagy.33 A hallmark of autoph-
agy is cytoplasmic accumulation of acidic vacuoles result-
ing from fusion of early autophagic vacuoles (autophago-
somes) to lysosomes or other acidic compartments from
the endocytic pathway.41 Treatment of HCC827 or H3255
cells with 3 M PI103 resulted in accumulation of cyto-
plasmic acid vacuoles identified by labeling with Lyso-
tracker green (Figure 4A). Cell populations treated with 3
M PI103 displayed increased intensity of Lysotracker
green fluorescence (Figure 4B) allowing for the quantifi-
cation of acidic vesicle accumulation by flow cytometry
(Figure 4C). In HCC827 cells, a progressive increase in
accumulation of acidic vesicles was observed after treat-
ment with 0.125 to 3 M of PI103 (Figure 4C). In H3255
cells, acidic vesicle accumulation was evident only after
treatment with 1 or 3 M of PI103 (Figure 4C).
Because PI103 treatment resulted in accumulation of
cytoplasmic acidic vesicles suggestive of autophagy, an
established autophagy biomarker was sought. During au-
tophagy, the protein LC3-I is incorporated into membrane
of autophagosomes via coupling to phosphatidylethano-
lamine.42 This lipidated form of LC3-I is termed LC3-II.
The electrophoretic mobility shift associated with conver-
sion of LC3-I to LC3-II during autophagosome formation
is detectable on LC3 western blots.41,42
A demonstrable increase in LC3-II, accompanied by
a decrease in LC3-I, was observed when HCC827 (parental
cells and induced and noninduced clones) or H3255 cells
were treated with 1 or 3 M of PI103 for 16 hours (Figures
4D and E). Treatment of HCC827 (induced and nonin-
duced clones) with PI103 (1 or 3 M, 16 hours) did not
result in cleavage of PARP (Figure 4E). LC3-II is de-
graded late in autophagy, when autophagosomes fuse with
lysosomes, forming autolysosomes. Therefore, increases in
LC3-II levels might indicate autophagy induction or a
block in protein degradation at the autolysosome.43 To
determine whether PI103 induced or blocked autophagy,
HCC827 cells were treated with PI103 in the presence of
the lysosomal protease inhibitors E64d and Pepstatin A.
TABLE 1. Sensitivity of NSCLC Cell Lines to MEK and PI3K/mTOR Inhibitor
Cell Line Doxycycline
IC50 Values (M)
PI-103 U0126 PD98059 Gefitinib CL-387,785
HCC827  0.74 10 20 0.015 0.001
HCC827 	 0.62 10 20 0.019 0.001
Clone D1  0.88 10 20 0.021 0.005
Clone D1 	 0.76 10 20 0.024 0.005
Clone D2  0.58 10 20 0.005 0.004
Clone D2 	 0.46 10 20 0.005 0.002
Clone T1  0.75 10 20 0.183 0.114
Clone T1 	 0.46 10 20 5 0.901
Clone T2  0.59 10 20 0.125 0.092
Clone T2 	 0.40 10 20 5 1.005
H3255  0.49 7.84 n.d. 0.021 0.001
Parental and clonal cell lines were subjected to MTT assays after 72 h of drug exposure, in the presence or absence of
doxycycline. IC50 values were calculated using the software GraphPad Prism.
NSCLC, non-small cell lung cancer; MEK, extracellular signal-regulated kinase kinase; PI3K, phosphatidylinositol 3-kinase;
mTOR, mammalian target of rapamycin; n.d., not done.
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FIGURE 4. Autophagy was induced by treatment of EGFR-TKI sensitive cell lines with PI103. A, HCC827 cells were labeled
with Lysotracker green during the last hour of treatment with DMSO or PI103 and observed live in an inverted microscope at
a magnification of 40X. B and C, Flow cytometry analysis of cells treated with PI103 or DMSO and labeled with Lysotracker
green. B, Cells treated with 3 M of PI103 show a clear increase in Lysotracker green fluorescence, indicating the accumula-
tion of acidic vacuoles. The R1 gate shown in this graph was arbitrarily defined so as to include cells with increased Lyso-
tracker green fluorescence compared with control, DMSO-treated cells (i.e., this gate excluded 90% of control cells). C,
Quantification of cells found in the R1 gate after treatment with increasing concentrations of PI103 for 16 hours. D, HCC827
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No increase in LC3-II levels in these conditions indicates
a block in autophagy.43 However, treatment with lysoso-
mal protease inhibitors and PI103 generated further accu-
mulation of LC3-II when compared with PI103 treatment
alone (Figure 4F), showing that PI103 induced autophagy.
Little or no cleaved PARP (a biomarker of apoptosis)
was detected in HCC827 or H3255 cells treated with PI103
for 16 hours (Figure 4D). Treatment with gefitinib or
CL-387785 was used as a positive control for the detection
of apoptosis. Surprisingly, these EGFR TKIs did not elicit
apoptosis in HCC827 cells after 16 hours of treatment,
whereas a strong signal corresponding to cleaved PARP
was observed readily after treatment of H3255 cells in the
same conditions (Figure 4D). Close examination of data in
the literature revealed that induction of apoptosis by ge-
fitinib or erlotinib seems to be delayed in HCC827 com-
pared with H3255 cells.12,38 Treatment of cells with PI-103
or gefitinib did not result in apoptosis, as assessed by
cleaved PARP in HCC827 cells, up to 48 hours of drug
exposure (Figure S6). Indeed, a recent report described the
effect of gefitinib as mainly cytostatic in a NSCLC cell line
expressing EGFR-Del (PC-9), in contrast to the proapop-
totic effect observed with H3255 cells.28 Treatment with
the autophagy inducer rapamycin (an mTORC1 inhibitor)
increased LC3-II levels in H3255 cells (but not in
HCC827) (Figure 4D).
Autophagy induction by PI103 was confirmed ultra-
structurally by the observation of autophagic vacuoles in
thin sections of TEM. HCC827 cells treated with DMSO
displayed normal cytoplasmic morphology in thin-section
TEM, with no evidence of increased autophagy (Figure
5A). In contrast, different types of autophagic vacuoles,
including autophagosomes (with double membrane and
cytoplasmic content) and smaller or larger (multives-
icular) autolysosomes (i.e., late autophagic vacuoles) were
often found by thin-section TEM in HCC827 cells treated
with PI103 (Figures 5B–D), confirming PI103 induced
autophagy.
DISCUSSION
The discovery of a link between activating EGFR
mutations in clinical NSCLC and response to the EGFR
TKIs gefitinib and erlotinib2–4 was a milestone in the field
of personalized cancer therapy. However, resistance
emerges in all patients who initially responded to these
agents highlighting the importance of seeking novel ther-
apies for lung cancers dependent on mutant EGFR activity.
Knowledge of the cell biology and drug sensitivity of cells
expressing drug resistance mutations must be considered
in the design of novel agents to prevent or overcome
acquired drug resistance in the clinic. The inducible ex-
pression of EGFR T790M in HCC827 cells described here
represents a robust, isogenic system to study the properties
conferred by this important drug resistance mutant to a
clinically relevant cell line.
It is not surprising that inducible expression of
EGFR-Del/T790M in HCC827 cells did not enhance cell
proliferation, increase activity of Akt, ERK1/2 or c-Src, or
result in obvious alterations of cell morphology, despite
the fact that all clones displayed increased EGFR phos-
phorylation after doxycycline treatment. The T790M mu-
tation in cis with an activating EGFR mutation has been
detected as a minor clone in clinical NSCLC samples
before treatment with gefitinib or erlotinib,44–47 suggesting
that these cells do not display improved proliferation in
vivo. Rather, EGFR T790M expressing cells seem to be
selectively amplified during drug treatment.
To date, studies associating EGFR T790M expres-
sion (in a background of an activating EGFR mutation) to
altered signaling or growth properties were performed by
constitutive expression and/or in cell systems where sen-
sitivity to EGFR TKIs was generated artificially.16,19,21
These systems are not isogenic (when constitutive expres-
sion is established) and/or might not be representative of
the context of NSCLC sensitive to EGFR TKIs, due to the
choice of cell line. Our results suggest that, in EGFR
TKI-sensitive NSCLC cells, where EGFR activity is in-
herently increased and required for proliferation and sur-
vival, further activation of downstream signaling pathways
by increased mutant EGFR expression is prevented by
regulatory mechanisms. Mulloy et al.22 report that the
EGFR T790M/L858R double mutant showed increased
oncogenic properties in comparison with the single mu-
tants. This was in contrast to the data presented here. This
may be explained by the different cell models employed to
study the effect of the T790M mutation. This highlights the
importance of studying mutant EGFR activity by inducible
(rather than constitutive) expression in a clinically relevant
cell background.
The in vitro data presented here does not, however,
exclude the possibility that changes mediated by acquired
EGFR T790M mutation in vivo have subtle effects on
tumor biology or on tumorigenesis, which might underlie
the observation that, in a mouse model of EGFR L858R/
T790M-induced lung tumorigenesis, EGFR L858R/T790M
expression resulted in formation of bronchial papillary
adenocarcinomas as well as the peripheral adenocarcino-
mas generated by EGFR L858R expression alone.17
FIGURE 4. (Continued). and H3255 cells were treated with different compound for 16 hours and prepared for Western blot-
ting for the detection of the autophagy marker LC3-II or the apoptosis marker cleaved PARP. Actin was used as a loading
control. The numbers in parenthesis after compound names represent the concentrations in M. E, D or T clones were grown
in the presence or absence of doxycycline for 24 hours before 16 hour-treatment with DMSO or PI103 and Western blotting
for the detection of LC3. F, HCC827 cells were treated for 16 hours with DMSO or PI103 alone or in combination with the
lysosomal protease inhibitors E64d and Pepstatin A before Western blotting for LC3 detection. EGFR, epidermal growth factor
receptor; TKI, tyrosine kinase inhibitor; DMSO, dimethyl sulfoxide; PI, PI103; U0, U0126; PD, PD98059; Gef., gefitinib; CL,
CL-387785; Rap., rapamycin.
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Inducible EGFR-Del/T790M expression in HCC827
cells faithfully recapitulated the resistance to lower con-
centrations of irreversible EGFR inhibitors observed in
model systems, and reinforced the idea (supported by early
clinical data) that these agents have modest activity against
NSCLC with acquired resistance to gefitinib and erlo-
tinib.17,24,25 MEK inhibition alone is also unlikely to sen-
sitize this type of NSCLC, according to our data and that
of others.28 Interestingly, our data show that up-regulation
and dephosphorylation of BIMEL alone, which occur on
MEK inhibition, are insufficient stimulus for apoptosis in
NSCLC cells with activating EGFR mutations. Treatment
with EGFR TKIs must elicit additional, MEK-indepen-
dent, proapoptotic stimuli to drive apoptosis in this con-
text. It remains possible that the combination of MEK
inhibitors with agents providing alternative proapoptotic
stimuli will be effective against EGFR TKI-resistant
NSCLC.
Importantly, our data show that NSCLC cells with
acquired resistance to gefitinib and erlotinib remain sensi-
tive to PI3K/mTOR inhibition. Treatment of HCC827 or
H3255 cells with PI103 resulted in markedly increased
autophagy, but little or no apoptosis. PI103 induces auto-
phagy in PC3 and U87MG cancer cell lines,33 although the
relationship between autophagy induction and Akt/mTOR
signaling down-regulation was not examined. In this study,
autophagy induction after treatment with 3 M of PI103
was associated with the lowest levels of Akt/mTOR activ-
ity, as determined by phosphorylation of Akt and p70S6K.
At this concentration, PI103 is expected to inhibit class I
PI3K and both mTOR containing complexes mTORC1 and
mTORC2,32 and this might be required for overt autophagy
induction.
The relationship between induction of a moderate
degree of autophagy and Akt/mTOR signaling down-reg-
ulation was complex and dependent on cell context. In
HCC827 cells, decreased phosphorylation of Akt and
p70S6K occurred at lower concentrations of PI103 (1
M) than those required for autophagy induction accord-
ing to LC3-II accumulation. However, some accumulation
of acidic vesicles occurred after treatment with 0.125 to
0.5 M PI103. Subtle increases in the transient autophagy
marker LC3-II (suggestive of some autophagy induction)
might have occurred after treatment with lower concentra-
tions of PI103 but were undetectable with the assays used.
In H3255 cells, autophagy was induced by 1 M of PI103
FIGURE 5. Autophagy induction
by PI103 was confirmed by ultra-
structural observation of treated
cells by TEM. A, Control, DMSO-
treated cells did not display signs of
increased autophagy. B, C, and D,
Early (arrowheads) or late (arrows)
autophagic vacuoles (autophago-
somes or autolysosomes, respec-
tively) could be found in the cyto-
plasm of cells treated with PI103 for
16 hours. TEM, transmission elec-
tron microscopy; DMSO, dimethyl
sulfoxide; N, nucleus.
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without obvious net down-regulation of Akt or mTOR
signaling. The moderate degree of autophagy induced by 1
M PI103 in H3255 cells might result from the inhibition
of mTOR-independent outputs of Akt activity, for which
Ser 473 dephosphorylation is not a reliable biomarker. In
fact, inhibition of Akt kinase activity results in increased
(rather than decreased) phosphorylation of Akt on Ser 473,
despite the fact that mTOR-independent outputs of Akt
activity are clearly inhibited.48
Taken together, the data presented here suggest that
combined inhibition of PI3K and mTOR could be of
clinical relevance in treatment of NSCLC with activating
EGFR mutations and for the prevention/treatment of ac-
quired resistance to EGFR TKIs. Our data also highlight
the fact that robust PI3K and mTOR inhibition are likely to
provoke autophagy. Although PI3K/mTOR inhibitors
might provide patient benefit due to a block of tumor cell
proliferation, the concomitant induction of autophagy
might have a more lasting negative effect of increasing
tumor cell survival. Comparison of the data presented in
this work with that of others31,32,49 suggests that robust
autophagy induction occurs at drug concentrations higher
than those required for cell proliferation inhibition. There-
fore, it is possible that a therapeutic window for PI3K/
mTOR inhibitors could be identified where cell prolifera-
tion is inhibited, with minimal autophagy induction.
However, further studies are now necessary to determine
the potential role of autophagy in this context as a cell
death rather than survival mechanism and the potential to
switch autophagic cell to apoptosis.
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